🇺🇸 FDA
Pipeline program

A study to assess the effects of efgartigimod on emasiprubart in healthy adult participants

ARGX-113-2405

Phase 1 other active

Quick answer

A study to assess the effects of efgartigimod on emasiprubart in healthy adult participants for not applicable is a Phase 1 program (other) at Argenx with 1 ClinicalTrials.gov record(s).

Program details

Company
Argenx
Indication
not applicable
Phase
Phase 1
Modality
other
Status
active

Clinical trials